KRAS and familial pancreatic carcinoma: ZC3HAV1, a PARP family enzyme, has been shown in pancreatic cancer to regulate cell cycle progression by modulating cyclin D1 and CDK2, and to bind KRAS, enhancing its expression and activating ERK signalling to promote proliferation and metastasis [47].